×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: US | Panel | Backs | Novartis | Pancreatic | Cancer | Drug

US Panel Backs Novartis' Pancreatic Cancer Drug

Tuesday, 12 April 2011 12:46 PM EDT

Novartis AG's cancer drug, Afinitor, showed safety and efficacy in treating a rare type of pancreatic cancer, a U.S. advisory panel said Tuesday.

The 10-member panel voted unanimously in favor of the drug's use in treating patients with advanced pancreatic neuroendocrine tumors.

Last Friday, the U.S. Food and Drug Administration staff questioned Novartis' findings on the benefits of the drug and the Swiss drugmaker narrowed the approval application after the reviewer's comments.

One study showed Afinitor extended the time it took the cancer to worsen in patients with advanced neuroendocrine tumors. The other study in patients with similar tumors missed its predefined statistical test for showing benefit, the FDA reviewers said Friday.

The drug is already approved for treating kidney cancer.

While a positive panel vote does not always lead to a regulatory approval, the FDA usually follows panel recommendations.

© 2024 Thomson/Reuters. All rights reserved.


Markets
Novartis AG's cancer drug, Afinitor, showed safety and efficacy in treating a rare type of pancreatic cancer, a U.S. advisory panel said Tuesday. The 10-member panel voted unanimously in favor of the drug's use in treating patients with advanced pancreatic neuroendocrine...
US,Panel,Backs,Novartis,Pancreatic,Cancer,Drug
140
2011-46-12
Tuesday, 12 April 2011 12:46 PM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Get Newsmax Text Alerts
TOP

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved